论文部分内容阅读
据1992年5月在美国加利福尼亚州圣迭戈市召开的AARC会议报道,介导多药抗性基因转入人骨髓细胞和应用成纤维细胞作为细胞因子表达载体是新的基因治疗策略。美国国立癌症研究所Gottesman指出,对化疗耐药的多种癌症,例如白血病、淋巴瘤、乳腺癌和卵巢癌,均可过量表达多药抗性1(MDR1)基因,该基因可保护人骨髓细胞免受化疗药物的毒性作用。实验中,他们从表达功能性人MDR1基因的转基因小鼠中获取骨髓,并植入正常小鼠,受体动物
According to the AARC conference held in San Diego, California, in May 1992, the introduction of multidrug resistance gene into human bone marrow cells and application of fibroblasts as cytokine expression vectors is a novel gene therapy strategy. Gottesman of the National Cancer Institute in the United States pointed out that many cancers that are resistant to chemotherapy, such as leukemia, lymphoma, breast cancer, and ovarian cancer, overexpress the multidrug resistance 1 (MDR1) gene, which protects human bone marrow cells. Protects against the toxic effects of chemotherapeutic drugs. In the experiment, they harvested bone marrow from transgenic mice expressing the functional human MDR1 gene and transplanted them into normal mice.